Nuvation Bio (NUVB)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from NUVB's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Nuvation Bio's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | — | $0 | $8M | $63M |
| Net income | -$87M | -$104M | -$76M | -$568M | -$205M |
| Free cash flow | — | — | — | -$130M | -$181M |
| EPS (diluted) | -$0.44 | -$0.48 | -$0.35 | -$2.11 | -$0.60 |
| Operating margin | — | — | — | -7527.3% | -338.7% |
Where the revenue comes from
Revenue by products, fiscal 2025. Every breakdown, year by year.
Superinvestors who own NUVB
From each investor's latest 13F filing (what a 13F shows). 5 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| Stanley Druckenmiller Duquesne Family Office |
Held | $26M | 0.50% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Added | $13M | 0.00% | Q2 2026 |
| David Abrams Abrams Capital Management |
Held | $7M | 0.13% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
New position | $1M | 0.00% | Q2 2026 |
| David Einhorn Greenlight Capital |
Held | $52,842 | 0.00% | Q4 2023 |
Insider buying
Open-market purchases by Nuvation Bio's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when NUVB trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Nuvation Bio insiders buying the stock?
No open-market insider purchases of NUVB in the last 12 months, according to SEC Form 4 filings.
Which superinvestors own Nuvation Bio?
5 of the superinvestors Investingly tracks hold NUVB in their latest 13F, including Stanley Druckenmiller, Cliff Asness, David Abrams.
Companies like Nuvation Bio
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.